CVS Plans to Separate Its Pharmacy and Insurance Businesses

A reversal of its integrated healthcare strategy

CVS Health plans to separate its businesses into two publicly traded companies, unwinding a major part of the integrated model it built through years of acquisitions. The Wall Street Journal reported on November 4 that the split is planned for early 2028 and that current shareholders would receive shares in both companies. One company would retain the CVS Health name and combine Aetna, pharmacy-benefit manager Caremark, Oak Street Health clinics, Signify Health home-care services and the specialty-drug business. The other, to be called CVS Pharmacy, would contain the retail and mail-order pharmacies, MinuteClinics and related consumer services. CVS operates roughly 9,000 retail pharmacies. The plan reverses part of the strategy behind CVS’s 2018 acquisition of Aetna for about $78 billion. That deal was intended to connect insurance, pharmacy benefits and retail drugstores in a single healthcare platform. Chief Executive David Joyner told the Journal that the businesses would be better served separately, with more focused management teams. Reuters also reported the planned separation, while noting that the earlier discussions had been at an initial stage. The later Journal report described a more definite decision and a proposed early-2028 timetable.

Regulatory scrutiny forms part of the backdrop

CVS has said the decision was not driven by regulatory pressure. Still, the structure of large pharmacy-benefit managers has faced increasing scrutiny from lawmakers and regulators. PBMs administer prescription-drug benefits for employers and health plans. Their work can include negotiating with manufacturers, setting formularies, contracting with pharmacies and processing claims. Critics argue that when one corporate group owns a PBM, an insurer and pharmacies, it may create conflicts of interest and make pricing less transparent. The Federal Trade Commission reached a settlement with Caremark in July 2026 that requires changes to certain business practices, including greater transparency and protections involving community pharmacies. The Department of Labor also finalized a PBM fee-disclosure rule in October, requiring covered service providers to disclose compensation and related payments to fiduciaries of large self-insured employer health plans. Those developments help explain the broader policy environment, but they do not prove that regulation caused CVS to split. Joyner has publicly framed the move as a business decision based on the companies’ readiness to operate independently.

The separation creates new tests for both companies

A standalone retail pharmacy company would have to compete without the same internal support from Aetna and Caremark. It would face pressure from online prescription delivery, changing consumer shopping habits, store operating costs and the challenges confronting traditional drugstores. The insurance-and-services company would need to demonstrate that Aetna and Caremark can continue to create value together, while its senior-care and home-health assets support its insurance business. The Financial Times initially reported that the proposed structure and timing remained uncertain. Reuters likewise described the discussions as early-stage at the time of its first report. The Journal subsequently provided a more detailed description of the two-company structure and the planned timetable. CVS’s investor-relations website scheduled a third-quarter 2026 earnings call for November 4, but the materials reviewed for this article did not include a complete separation filing, detailed pro forma financial statements or a final transition-services agreement. The strategic rationale is clear: CVS believes two more focused businesses may be easier to manage and value. The execution risks are equally important. Investors will need to assess how assets and liabilities are allocated, what costs are stranded, how shared services are handled, and whether each company can maintain its competitive position after the separation. The proposed split is therefore not simply a corporate reorganization; it is a test of whether CVS’s formerly integrated businesses can create more value on their own.